HLS Therapeutics (HLTR.F) Stock Overview
A specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HLTR.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
HLS Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.21 |
| 52 Week High | CA$4.02 |
| 52 Week Low | CA$2.96 |
| Beta | 0.81 |
| 1 Month Change | -4.52% |
| 3 Month Change | -4.52% |
| 1 Year Change | 8.45% |
| 3 Year Change | -31.05% |
| 5 Year Change | -81.10% |
| Change since IPO | -50.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLTR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.0% | 0.7% | 3.4% |
| 1Y | 8.4% | 43.5% | 29.7% |
Return vs Industry: HLTR.F underperformed the US Pharmaceuticals industry which returned 43.5% over the past year.
Return vs Market: HLTR.F underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| HLTR.F volatility | |
|---|---|
| HLTR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: HLTR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HLTR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels.
HLS Therapeutics Inc. Fundamentals Summary
| HLTR.F fundamental statistics | |
|---|---|
| Market cap | US$99.45m |
| Earnings (TTM) | -US$12.43m |
| Revenue (TTM) | US$55.50m |
Is HLTR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLTR.F income statement (TTM) | |
|---|---|
| Revenue | US$55.50m |
| Cost of Revenue | US$15.79m |
| Gross Profit | US$39.71m |
| Other Expenses | US$52.14m |
| Earnings | -US$12.43m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 71.55% |
| Net Profit Margin | -22.40% |
| Debt/Equity Ratio | 79.1% |
How did HLTR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 01:31 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLS Therapeutics Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |